Lung Cancer

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.

Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more personalized and effective treatment.

Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC.

The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, outperforming historical data.

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

Dr. Daniel J. Boffa shared how cancer care teams support patients in quitting smoking and how new data may guide improvements in high-smoking U.S. regions.

Lung cancer remains the leading cause of cancer-related deaths in the U.S.

LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.

Lung Cancer Initiative proudly participated in the GO2 Voices Summit held March 9–11, 2025, in Washington, DC.

Dr. Daniel J. Boffa discusses the link between smoking cessation and increase in survival for people who are active smokers and diagnosed with cancer.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.

The strongest connections I’ve made are with others who have also been through their own cancer journeys.

Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.

Enrollment and initial dosing of PAS-004 at 30 milligrams has begun in three patients with MAPK pathway-driven advanced solid tumors.

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

Dr. Douglas Reznick shares advice for patients with lung or head and neck cancer who may feel overwhelmed by their diagnosis.

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.